A system for drug discovery and development based on artificial intelligence

Abstract

An artificial intelligence system for drug discovery and development, consisting of: a data integration module configured to collect and process pharmaceutical data from multiple sources, including molecular structures, protein-protein interactions, drug-protein interactions, and clinical trial data, and to standardize the collected data into a uniform format; a machine learning engine configured to: analyze the standardized data using deep learning algorithms, generate predictive models for drug-protein interactions, and identify potential drug candidates based on molecular features; a drug development module configured for the following purposes: generation of novel molecular structures using generative contradictory networks, evaluation of the synthetic feasibility of generated molecules, and prediction of the biological activities of developed molecules; A clinical trial optimization module configured to: analyze patient data to select optimal study participants; predict drug efficacy based on molecular and patient-related characteristics; and create study protocols based on the predicted outcomes; and a validation module configured for evaluating the accuracy of generated predictions, validating synthetic routes for drug candidates, and assessing the safety profiles of developed molecules.

Description

FIELD OF THE INVENTION

[0001] This disclosure relates to a system for artificial intelligence-assisted drug discovery and development. BACKGROUND OF THE INVENTION

[0002] The pharmaceutical industry has traditionally relied on fixed processes and batch-based workflows for drug development and manufacturing, pursuing a "one-size-fits-all" approach that limits the possibilities for personalized medicine. While advances in genomics and diagnostics enable more personalized pharmaceutical approaches, current manufacturing methods and technologies cannot meet these evolving needs.

[0003] The industry faces several critical challenges. First, the development and commercial-scale production of complex, safe-for-human drugs is hampered by technological limitations. Second, the industry has shown little innovation in developing new machinery and technologies for drug development. Third, traditional drug development methods are time-consuming and costly and do not offer the flexibility required for personalized medicine.

[0004] Recent advances in artificial intelligence, particularly deep learning frameworks, have shown promising opportunities to overcome these limitations. Unlike traditional computational methods, deep learning algorithms can autonomously learn features from input data and transform simple attributes into complex representations through multi-layered processing. This capability offers new opportunities to revolutionize drug discovery, design, and development processes.

[0005] The integration of AI into drug development has gained increasing importance, particularly in four key areas: assessing disease severity and predicting treatment outcomes, preventing complications during treatment, providing supportive technology during treatment, and developing new applications for existing tools and chemistries to improve safety and efficacy. These applications demonstrate the potential of AI to transform the pharmaceutical industry by enabling more efficient, personalized, and innovative approaches to drug development.

[0006] In view of the previous discussion, it is clear that there is a need for a drug discovery and development system based on artificial intelligence. SUMMARY OF THE INVENTION

[0007] The present disclosure relates to a drug discovery and development system based on artificial intelligence. The invention provides a drug discovery and development system based on artificial intelligence that integrates multiple computer modules for efficient and personalized drug development. The system combines deep learning algorithms, predictive analytics, and automated validation processes to streamline drug design, optimize clinical trials, and improve manufacturing processes. This integrated approach enables the development of personalized medicines while reducing development time and costs.

[0008] This disclosure is intended to provide a system for drug discovery and development based on artificial intelligence. The system comprises: a data integration module configured to: collect and process pharmaceutical data from multiple sources, including molecular structures, protein-protein interactions, drug-protein interactions, and clinical trial data, and standardize the collected data into a unified format; a machine learning engine configured to: analyze the standardized data using deep learning algorithms; generate predictive models for drug-protein interactions; and identify potential drug candidates based on molecular features; a drug design module configured to: generate new molecular structures using generative adversarial networks;evaluates the synthetic feasibility of generated molecules; and predicts the biological activities of designed molecules; a clinical trial optimization module configured to: analyze patient data for optimal selection of study participants; predict drug efficacy based on molecular and patient characteristics; and generate study protocols based on the predicted outcomes; and a validation module configured to: evaluate the accuracy of generated predictions; validate synthetic pathways for drug candidates; and evaluate safety profiles of designed molecules.

[0009] One objective of this disclosure is to provide an artificial intelligence system to support drug discovery and development.

[0010] Another objective of this disclosure is to provide an automated system to accelerate drug discovery and development through artificial intelligence and deep learning algorithms.

[0011] Another objective of this disclosure is to enable the development of personalized medicines by integrating patient-specific data into drug design processes.

[0012] Another objective of this disclosure is to optimize pharmaceutical manufacturing processes through predictive analytics and real-time monitoring.

[0013] To further clarify the advantages and features of the present disclosure, a more detailed description of the invention will be given with reference to specific embodiments thereof illustrated in the accompanying drawings. It should be noted that these drawings represent only typical embodiments of the invention and are therefore not to be considered limiting its scope. The invention will be described and explained in additional detail and in greater detail with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE CHARACTERS

[0014] These and other features, aspects, and advantages of the present disclosure will be better understood when the following detailed description is read with reference to the accompanying drawings, in which like characters represent like parts throughout. Fig. 1 shows a block diagram of an artificial intelligence-based drug discovery and development system according to an embodiment of the present disclosure. And Fig. Figure 2 shows a diagram illustrating connections between AI, ML, and DL for drug development according to an embodiment of the present disclosure.

[0015] Furthermore, those skilled in the art will appreciate that elements in the drawings are shown for convenience and may not necessarily be drawn to scale. For example, the flowcharts illustrate the method by key steps to enhance understanding of aspects of the present disclosure. Moreover, with respect to device construction, one or more components of the device may have been represented in the drawings by conventional symbols, and the drawings may show only those specific details relevant to understanding embodiments of the present disclosure in order not to clutter the drawings with details that would be readily apparent to those skilled in the art who would benefit from the description herein. DETAILED DESCRIPTION:

[0016] To facilitate an understanding of the principles of the invention, reference will now be made to the embodiment illustrated in the drawings and described in specific language. It is to be understood, however, that this is not intended to limit the scope of the invention, as such changes and further modifications to the illustrated system and such further applications of the principles of the invention as illustrated therein are contemplated as would normally occur to one skilled in the art to which the invention pertains.

[0017] It will be understood by one skilled in the art that the foregoing general description and the following detailed description are exemplary and explanatory of the invention and are not intended to be limiting thereof.

[0018] References in this specification to "one aspect," "another aspect," or similar language mean that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present disclosure. Therefore, occurrences of the phrase "in one embodiment," "in another embodiment," and similar language throughout this specification may or may not all refer to the same embodiment.

[0019] The terms "comprises," "comprising," or other variations thereof are intended to cover non-exclusive inclusion, such that a process or method comprising a list of steps not only includes those steps, but may also include other steps not expressly listed or inherent in such process or method. Likewise, one or more devices or subsystems or elements or structures or components preceded by "comprises...a" does not preclude, without further limitation, the existence of other devices or other subsystems or other elements or other structures or other components or additional devices or additional subsystems or additional elements or additional structures or additional components.

[0020] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The system, methods, and examples provided herein are for illustrative purposes only and should not be considered limiting.

[0021] Embodiments of the present disclosure will be described in detail below with reference to the accompanying drawings.

[0022] The functional units described in this specification have been referred to as devices. A device may be implemented in programmable hardware devices such as processors, digital signal processors, central processing units, field-programmable gate arrays, programmable array logic, programmable logic devices, cloud processing systems, or the like. The devices may also be implemented in software for execution by various types of processors. An identified device may contain executable code and may, for example, comprise one or more physical or logical blocks of computer instructions, which may be organized, for example, as an object, procedure, function, or other construct.However, the executable file of an identified device need not be physically located together, but may comprise different instructions stored in different locations which, when logically linked together, constitute the device and fulfill the stated purpose of the device.

[0023] Indeed, executable code of a device or module may be a single instruction or multiple instructions, and may even be distributed across several different code segments, among different applications, and across multiple storage devices. Similarly, operational data may be identified and represented within the device and embodied in any suitable form and organized in any suitable type of data structure. The operational data may be captured as a single set of data or distributed across different locations, including different storage devices, and may exist, at least in part, as electronic signals in a system or network.

[0024] References in this specification to "a selected embodiment," "an embodiment," or "an embodiment" mean that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the disclosed subject matter. Therefore, the appearances of the phrases "a selected embodiment," "in an embodiment," or "in an embodiment" in various places in this specification do not necessarily refer to the same embodiment.

[0025] Furthermore, the described features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. In the following description, numerous specific details are provided to provide a thorough understanding of embodiments of the disclosed subject matter. However, one of ordinary skill in the art will recognize that the disclosed subject matter may be practiced without one or more of the specific details, or with different methods, components, materials, etc. In other instances, well-known structures, materials, or operations are not shown or described in detail to avoid obscuring aspects of the disclosed subject matter.

[0026] According to the example embodiments, the disclosed computer programs or modules may be executed in many example ways, for example, as an application stored in the memory of a device or as a hosted application running on a server and communicating with the device application or browser using a variety of standard protocols such as TCP / IP, HTTP, XML, SOAP, REST, JSON, and other suitable protocols. The disclosed computer programs may be written in example programming languages ​​that execute from memory on the device or from a hosted server, for example, BASIC, COBOL, C, C++, Java, Pascal, or scripting languages ​​such as JavaScript, Python, Ruby, PHP, Perl, or other suitable programming languages.

[0027] Some of the disclosed embodiments comprise or otherwise involve data transmission over a network, such as communicating various inputs or files over the network. The network may comprise, for example, one or more of the following: the Internet, wide area networks (WANs), local area networks (LANs), analog or digital wired and wireless telephone networks (e.g., a PSTN, Integrated Services Digital Network (ISDN), a cellular network, and Digital Subscriber Line (xDSL)), radio, television, cable, satellite, and / or any other delivery or tunneling mechanism for transmitting data. The network may comprise multiple networks or subnetworks, each of which may comprise, for example, a wired or wireless data path. The network may comprise a circuit-switched voice network, a packet-switched data network, or any other network capable of transmitting electronic communications.For example, the network may include networks based on Internet Protocol (IP) or Asynchronous Transfer Mode (ATM), and may support voice using, for example, VoIP, Voice over ATM, or other comparable protocols used for voice data communications. In one implementation, the network includes a cellular network configured for the exchange of text or SMS messages.

[0028] Examples of the network include, but are not limited to, a Personal Area Network (PAN), a Storage Area Network (SAN), a Home Area Network (HAN), a Campus Area Network (CAN), a Local Area Network (LAN), a Wide Area Network (WAN), a Metropolitan Area Network (MAN), a Virtual Private Network (VPN), an Enterprise Private Network (EPN), the Internet, a Global Area Network (GAN), and so on.

[0029] Fig. 1 shows a block diagram of a system (100) for artificial intelligence-driven drug discovery and development according to an embodiment of the present disclosure.

[0030] With reference to Fig. 1, the system (100) comprises a data integration module (102) configured to collect and process pharmaceutical data from multiple sources, including molecular structures, protein-protein interactions, drug-protein interactions, and clinical trial data, and to standardize the collected data into a uniform format; a machine learning engine (104) configured to analyze the standardized data using deep learning algorithms, generate predictive models for drug-protein interactions, and identify potential drug candidates based on molecular features; a drug design module (106) configured to generate novel molecular structures using generative adversarial networks, evaluate the synthetic feasibility of generated molecules, and predict biological activities of developed molecules;a clinical trial optimization module (108) configured to analyze patient data for optimal selection of study participants, predict drug efficacy based on molecular and patient characteristics, and generate study protocols based on the predicted results; and a validation module (110) configured to evaluate the accuracy of generated predictions, validate synthetic pathways for drug candidates, and evaluate the safety profiles of developed molecules.

[0031] In one embodiment, the machine learning engine (104) comprises: a deep neural network configured to analyze protein structures; a convolutional neural network configured to process molecular images; a recurrent neural network configured to generate molecular structures; and a reinforcement learning module configured to optimize molecular properties.

[0032] In one embodiment, the drug design module (106) is further configured to perform retrosynthesis planning using Monte Carlo tree search algorithms, predict reaction yields for proposed synthesis routes, and optimize reaction conditions based on the predicted results.

[0033] In one embodiment, the data integration module (102) is further configured to implement natural language processing to extract information from the scientific literature; maintain a knowledge graph of drug-target interactions; and update the database in real time with new experimental data.

[0034] In one embodiment, the clinical trial optimization module (108) is further configured to analyze patient dropout patterns using predictive analytics, generate personalized dosing recommendations, and monitor patient compliance via mobile applications.

[0035] In one embodiment, the validation module (110) is further configured to perform cross-validation using a time-split method, generate confidence scores for predictions, and determine potential drug side effects through network analysis.

[0036] In one embodiment, the system (100) further comprises a manufacturing optimization module (112) configured to simulate production processes using computational fluid dynamics, optimize granulation parameters, and predict quality control results.

[0037] In one embodiment, the drug design module (106) implements quantitative structure-activity relationship (QSAR) analysis, molecular docking simulations, and binding affinity predictions using deep learning.

[0038] In one embodiment, the system (100) further comprises a drug delivery optimization module (114) configured to design nanobot-based delivery systems, predict drug-drug interactions, and optimize drug release profiles.

[0039] In one embodiment, the machine learning engine (104) uses transfer learning techniques configured to use pre-trained models for sparse data scenarios, adapt learned features to different drug discovery tasks, and optimize model parameters for specific molecular targets.

[0040] The present invention relates to a drug discovery and development system based on artificial intelligence. The system operates through interconnected modules that process pharmaceutical data using advanced AI algorithms. The data integration module collects and standardizes information from multiple sources, while the machine learning engine analyzes this data to create predictive models. The drug design module uses these predictions to create novel molecular structures and evaluate their feasibility. The clinical trial optimization module selects optimal study participants and predicts drug efficacy. The validation module ensures accuracy through continuous evaluation of predictions and safety profiles.These modules work together to enable rapid, efficient and personalized drug development while maintaining high safety standards.

[0041] Fig. Figure 2 shows a diagram illustrating connections between AI, ML, and DL for drug development according to an embodiment of the present disclosure.

[0042] Machine learning is increasingly being used to address critical challenges in drug discovery and development. A comprehensive review of recent advances, emerging technologies, and significant research contributions in this field was conducted. Relevant studies were identified through a systematic literature search using targeted keywords related to advanced technology and machine learning applications in drug discovery. The search focused on publicly available databases covering a specific time period. After evaluating the studies based on their relevance, abstracts, and approaches, approximately 36 studies were selected for inclusion in this review.

[0043] Drug design and development play a crucial role in pharmaceutical research, as molecules must meet certain criteria to be considered as potential drug targets. A molecule's ability to interact with biological systems determines its viability, making druggability a key factor in the selection process. In the post-genomic era, drug discovery has shifted toward more innovative approaches to create molecules capable of binding to, modulating, or degrading challenging biological targets. This transition is driving the development of breakthrough medicines. Traditionally, pharmaceutical discovery has prioritized the development of orally bioavailable small molecules targeting established druggable sites.The introduction of Lipinski's five-point rule (Ro5) provides a framework for predicting potential absorption and permeability problems. Ro5 defines specific thresholds for hydrogen bond donors, hydrogen bond acceptors, molecular weight, and lipophilicity, thus aiding in the discovery of small molecules.

[0044] While Ro5-compatible small molecules have been extensively explored, there is increasing interest in finding new, less conventional targets for drug development. This has led to the exploration of molecular modalities beyond Ro5, including bifunctional molecules such as PROTACs, peptides, peptidomimetics, oligonucleotides, and carbohydrate-based drugs. Carbohydrates pose a challenge due to their low druggability and require innovative approaches to enhance their therapeutic potential. Lipid-based drug discovery has also gained attention, with a focus on lipid signaling pathways and enzymes critical to cellular processes. The majority of approved drug targets are proteins, which require specific binding sites to effectively interact with drug-like molecules.The identification and validation of such druggable proteins remains a significant challenge given the limited knowledge of protein targets and their role in disease mechanisms. Traditional computational approaches have played an important role in identifying and characterizing protein-ligand interactions. However, these approaches often lack precision, particularly with complex datasets from genomics, proteomics, and clinical trials. Artificial intelligence and machine learning have ushered in a revolutionary transformation in drug discovery, overcoming the limitations of previous computational techniques. AI-powered advances, including artificial neural networks and deep learning algorithms, have significantly improved various aspects of drug design.These systems enable accurate predictions of protein structure and function, optimize lead compounds, and evaluate properties related to absorption, distribution, metabolism, excretion, and toxicity. AI has also been applied to peptide synthesis, virtual screening for structure- and ligand-based interactions, toxicity prediction, pharmacophore modeling, quantitative analysis of structure-activity relationships, drug repositioning, and polypharmacology.

[0045] Cutting-edge data mining, curation, and management strategies further enhance these advances and ensure that AI-driven systems can be effectively used in drug discovery. By integrating machine learning and AI into pharmaceutical research, drug development is undergoing a transformation that accelerates the identification of promising drug candidates while improving precision and efficiency.

[0046] Protein structure prediction plays a crucial role in structure-based drug development, as most diseases are associated with malfunctioning proteins. Although sequence data for most proteins are available, accurately determining their three-dimensional structure remains challenging due to computational complexity and cost. Recent advances in deep learning have led to significant breakthroughs, enabling more precise prediction of secondary structures, backbone torsion angles, and residue contacts. A powerful approach involves integrating one- and two-dimensional protein data using combinatorial neural networks, thereby improving the accuracy of residue contact predictions. This approach has demonstrated superior performance in competitions evaluating structure prediction techniques.Despite these advances, achieving high-precision de novo three-dimensional structural predictions remains an important goal.

[0047] Protein interactions play a fundamental role in biological systems and are often linked to various diseases. Large databases collect extensive interaction data by incorporating information from experimental research, computational predictions, and curated literature. Advanced artificial intelligence models continue to improve the prediction and understanding of these interactions, driving drug discovery efforts. Artificial intelligence-based innovations are reshaping drug discovery by accelerating research, uncovering new targets, and refining therapeutic design. These advances contribute to the rapid development of next-generation medicines and benefit global healthcare.

[0048] Protein interactions extend beyond traditional targets such as ion channels, kinases, and nuclear receptors, offering improved biological specificity and reducing side effects. Selectively engineered compounds can effectively block specific signaling pathways in diseased cells without harming normal tissue, thus offering promising therapeutic options. This expanded target space enables the development of small molecule modulators and promotes therapeutic innovation. Understanding the structural properties of protein complexes is critical for developing drugs that effectively target them. Interaction interfaces encompass multiple residues and possess large buried surface areas, where specific regions contribute significantly to the binding energy and serve as important drug-accepting sites.Computational strategies have been developed to identify these critical regions, cluster smaller binding sites, and optimize interaction sites based on evolutionary conservation. These advances help identify promising targets and refine molecular design.

[0049] Predicting drug-protein interactions is critical for evaluating efficacy, repurposing existing drugs, and minimizing unintended side effects. Artificial intelligence-driven systems leveraging various learning frameworks have significantly improved the accuracy of predictions of ligand-protein interactions. Models trained on large datasets of known interactions have successfully identified new molecules capable of targeting key proteins. Computational frameworks that integrate pharmacological and chemical data provide highly sensitive and specific interaction predictions, outperforming traditional approaches. Artificial intelligence also accelerates the discovery of new applications for existing drugs and makes drug development more cost-effective.Algorithms have successfully repurposed existing compounds by identifying their potential to treat diseases beyond their original indications. Predictive tools enable a deeper understanding of therapeutic effects and potential side effects, supporting the safe and efficient development of novel treatments.

[0050] Artificial intelligence has revolutionized drug design by overcoming the limitations associated with traditional approaches, such as complex synthetic pathways and unpredictable biological effects. Generative models capable of generating novel chemical structures tailored to specific targets have demonstrated extraordinary success. These models, trained on large-scale molecular datasets, generate diverse compound libraries with precise chemical properties. Sophisticated synthesis planning systems suggest efficient routes for developing both patented and novel compounds and optimize drug formulation. Reinforcement-based learning frameworks integrate predictive models with molecular evolution strategies, enhancing the ability to generate unique molecules while accurately estimating their properties.These advances significantly accelerate drug identification and refinement and offer significant advantages in pharmaceutical research.

[0051] The combination of predictive precision and rapid drug development has made artificial intelligence an indispensable tool in drug discovery. By leveraging massive datasets and advanced learning techniques, researchers can develop safer and more effective drugs while optimizing the development pipeline.

[0052] Drug repurposing, also known as drug repositioning, involves discovering new therapeutic applications for already approved drugs. This approach significantly shortens development time and reduces the risks typically associated with bringing new drugs to market. Many drugs can interact with multiple targets, resulting in distinct biological effects. For example, metformin, originally used to treat type 2 diabetes, has shown the potential to extend lifespan. In this framework, drugs and diseases are the central components, while drug targets and disease-associated genes play crucial roles. Due to the complexity of these interactions, network analysis becomes indispensable for mapping relationships.Nine interconnected networks contribute to drug repurposing: gene regulatory, metabolic, protein-protein, drug-target, drug-drug, drug-disease, target-disease, drug-side effect, and disease-disease networks. The fundamental principle of network-based approaches is that drugs with similar properties tend to have overlapping targets or effects.

[0053] Individual networks often provide limited and fragmented information, requiring the integration of multiple networks into a composite structure to achieve greater accuracy. A prominent example of this system is DTINet, which uses sophisticated techniques such as network diffusion and dimensionality reduction to synthesize information from different networks to uncover new targets and therapeutic opportunities. The system has identified previously unknown cyclooxygenase-inhibiting properties in compounds such as alendronate, chlorpropamide, and telmisartan. Experimental validation confirmed their ability to reduce pro-inflammatory mediators, highlighting their potential as anti-inflammatory agents.

[0054] Virtual screening uses computational intelligence to identify bioactive compounds from large chemical libraries, either in-house or commercially available. This system facilitates the discovery of promising drug candidates while filtering out those with unsuitable chemical structures. It is generally divided into structure-based and ligand-based approaches and uses techniques such as docking, pharmacophore modeling, similarity assessment, and machine learning-based predictions. Structure-based virtual screening is based on molecular docking when the three-dimensional structure of a target protein is available. Although it is highly effective in identifying potential drug candidates, certain challenges exist.Docking scores often fail to accurately predict binding affinities because solvation effects and entropy are not sufficiently considered. Protein flexibility further complicates predictions, and docking scores tend to prioritize binding affinity while overlooking critical aspects such as residence time. Therefore, false positive results remain a persistent problem in docking-based virtual screening.

[0055] The central component of molecular docking is its scoring function, which determines how effectively a drug-like compound binds to a given target. Machine learning-based scoring functions have enhanced this capability by analyzing a wide range of geometric, chemical, and physical properties more efficiently than traditional models. These data-driven scoring systems predict ligand-protein binding affinities directly from experimental data, eliminating the need for extensive physical simulations. Algorithms such as random forest and support vector machine have proven superior in refining docking-based scoring. For example, support vector machine models nonlinear relationships between energy terms from docking algorithms and experimentally observed binding affinities, resulting in higher prediction accuracy.Likewise, the integration of Random Forest into docking platforms has led to significant improvements.

[0056] Recent advances in deep learning have further transformed activity assessment, particularly through the application of convolutional neural networks. These networks process images of protein-ligand interactions and provide highly accurate predictions of binding affinity. A 3D graph-based convolutional neural network model has been shown to generate strong correlations between predicted and experimental binding affinities. More advanced deep learning systems such as DeepVS capture complex molecular features with the highest accuracy and outperform conventional docking models in widely accepted benchmarks. These innovations further refine drug discovery, making it more efficient and reliable.

[0057] In the hit-to-lead phase, quantitative structure-activity relationship (QSAR) analysis plays a crucial role in identifying promising lead candidates by predicting the biological effects of related molecules. This approach relies on mathematical models to establish quantitative connections between molecular structures or physicochemical properties and their biological activities. The system encompasses several key steps, including data acquisition, molecular descriptor selection, model generation, evaluation, and application. The selection of descriptors and the mathematical models representing structure-activity relationships are particularly important for refining predictions. Early developments introduced fundamental principles by correlating chemical structures with biological activities.Some approaches included physicochemical parameters such as hydrophobicity and electronic effects, while others predicted activity based on structural variations.

[0058] With the advent of machine learning, QSAR modeling has evolved significantly, enabling the development of sophisticated predictive models. Algorithms with advanced learning mechanisms have improved the accuracy of these models, while deep learning architectures have opened up new possibilities for dealing with complex chemical features. Multitasking deep neural networks have demonstrated superior performance by identifying common features across related tasks, thus achieving notable improvements in predictive capabilities. The integration of deep learning techniques into platforms designed for drug discovery has consistently outperformed traditional learning-based techniques and demonstrated higher reliability in various applications.Furthermore, deep learning models using 2D molecular descriptors have outperformed conventional force field-based approaches in predicting activity and binding affinities, setting a new standard in hit-to-lead optimization by providing improved predictive power and efficiency.

[0059] De novo drug design enables the creation of new chemical structures tailored to specific biological functions. Traditional fragment-based techniques, which generate compounds from scratch, often face challenges due to the complexity of molecular architectures and the difficulty in assessing biological effects. The introduction of artificial intelligence has revolutionized this field by facilitating the development of molecular structures with desired properties. By training neural networks on molecular structures encoded in a specialized format, systems can generate new molecules based on learned patterns. Reinforcement mechanisms improve this process by rewarding the generation of structures with favorable activity values, thus ensuring high accuracy in predicting biological activity.

[0060] Another breakthrough utilizes coding systems that convert molecular structures into latent space representations, which can then be decoded back into molecular designs. Predictive modeling further refines these representations and optimizes chemical properties for improved effectiveness. Some architectures introduce grammatical constraints to maintain molecular validity and enforce chemical plausibility, thereby improving the reliability of the generated compounds. Furthermore, generative architectures trained on molecular fingerprints have demonstrated superior performance in reconstruction accuracy, generative capability, and feature extraction, further improving the efficiency of molecular design.To ensure synthetic feasibility, specialized scoring systems analyze chemical reactions, filter out impractical molecules, and optimize the drug discovery chain. These innovations have significantly improved the ability to design novel, functionally relevant compounds.

[0061] The prediction of retrosynthetic pathways for complex molecules has also undergone a transformation with the integration of artificial intelligence. By breaking molecules down into simpler, more accessible precursors, advanced search algorithms efficiently explore reaction pathways. Previous computational tools required extensive human intervention and lacked chemical intuition, but modern learning-based systems trained on vast reaction datasets can now predict optimal transformation steps, reaction probabilities, and high-yield synthesis pathways. By incorporating neural networks at various stages, an intelligent framework is capable of expanding potential reaction nodes, evaluating pathways, and dynamically updating the search process.The efficiency of this approach enables solutions to most retrosynthesis problems within seconds, achieving unprecedented speed and reliability compared to conventional techniques.

[0062] Artificial intelligence also plays a crucial role in predicting yields in chemical reactions. By analyzing the properties of reactants, learning-based models can accurately predict yields for complex reactions. Molecular descriptors, including vibrational frequencies and dipole moments, are used to improve prediction accuracy, enabling efficient optimization of chemical transformations. The automation of chemical synthesis has further streamlined workflows and reduced reliance on manual processes. Sophisticated platforms encode chemical recipes into standardized digital formats, enabling the robotic execution of synthesis procedures. These autonomous systems have successfully synthesized high-purity pharmaceuticals and demonstrated the potential for fully automated, reproducible chemistry.By integrating learning-based techniques, digital standardization, and robotic execution, this approach has redefined chemical synthesis, improving precision and scalability.

[0063] In computer-aided drug design, the effective representation of molecules is crucial. Traditional approaches rely on 2D structural diagrams, but modern cheminformatics has introduced machine-readable formats that enable more advanced processing of chemical data. Machine learning models have shown the ability to extract meaningful chemical features from small datasets, which is particularly useful in drug discovery, where data is often limited.

[0064] Deep learning techniques typically require large datasets for training, which can be challenging when data is limited. To overcome this problem, transfer learning leverages knowledge from related datasets to improve prediction accuracy on smaller datasets. One-shot learning techniques create meaningful distance metrics using related data, enabling predictions even with minimal training examples. The combination of graph convolutional neural networks and recurrent networks has demonstrated superior performance compared to traditional models such as random forests, particularly on datasets related to toxicity and side effects. This highlights the potential of transfer learning in addressing data sparsity challenges in drug discovery.

[0065] Evaluating the performance of predictive models is a crucial aspect of AI-driven drug development. Random-split cross-validation is a common approach, but it often leads to overly optimistic predictions by mixing data from independent sources and ignoring covariate changes that are critical for drug development. An alternative approach, time-split cross-validation, structures datasets based on their chronological order, allowing for a more realistic assessment of predictive performance. Research has shown that this approach provides accuracy metrics that better reflect real-world outcomes than random-split cross-validation. Time-critical experimental data particularly benefit from this approach, as it ensures robust validation of predictive models.

[0066] Despite their superior predictive power, deep learning models pose challenges due to their complex architectures and large number of parameters. These challenges become even more pronounced when data is limited or features are sparse, often leading to local optima and reduced accuracy. Pretraining techniques such as deep belief networks have been introduced to improve parameter initialization and achieve better results compared to random initialization. Furthermore, dropout techniques have been widely adopted to prevent overfitting in predictive modeling for drug discovery. Activation functions play a key role in improving model efficiency, with the Rectified Linear Unit (ReLU) emerging as a preferred choice over traditional functions such as sigmoid, as it prevents gradient vanishing and improves optimization.

[0067] The pharmaceutical industry has benefited significantly from AI-assisted drug development through the integration of software tools. Many developers now share AI-assisted frameworks on open-source platforms, making these innovations widely accessible. These repositories provide important tools that accelerate the adoption of AI technologies and enable researchers and industry professionals to integrate advanced computational techniques into drug discovery.

[0068] AI technologies are having a significant impact on the pharmaceutical industry, contributing to various phases of the drug development lifecycle. While no single market solution currently covers all applications, AI-driven innovations are transforming drug discovery, clinical trials, manufacturing, and quality control. Natural language processing (NLP) models such as BERT and GPT facilitate document summarization and generation, named entity recognition (NER), and support real-world evidence (RWE)-based study reports and automated document generation. Machine learning algorithms, including Random Forest, Naive Bayes, and Support Vector Machines, analyze unstructured data to identify potential drug targets, accelerating the discovery of new therapies.Deep neural networks, reinforcement learning, and principal component analysis improve the generation of virtual molecules and activity prediction, while text mining and feedforward neural networks contribute to drug repurposing. AI applications in synthetic biology support RNA sequencing, and real-world data, combined with AI, optimizes clinical trials. Convolutional neural networks process preclinical and clinical data through advanced image analysis, and neural networks improve personalized therapies by integrating genetic and environmental factors to assess patient risk. AI also refines drug delivery by analyzing electronic medical records to detect contraindications and drug interactions.In addition, AI contributes to the monitoring and prediction of global epidemics and ensures that drug strategies remain adapted to the new challenges in healthcare.

[0069] The development and formulation of new drug compounds has traditionally been based on trial and error, but AI offers a more efficient alternative. Computational techniques optimize formulation design by evaluating stability, dissolution, and porosity using models of quantitative structure-property relationships. Decision support systems incorporate rule-based algorithms to determine excipient types and amounts based on a drug's physicochemical properties, with feedback loops ensuring continuous improvement. A hybrid system integrating model expert systems with artificial neural networks was used to improve the formulation of piroxicam capsules and achieve compliance with dissolution standards.While model expert systems suggest formulation options, artificial neural networks use backpropagation training to establish connections between these options and the desired results. Numerical fluid dynamics, discrete element modeling, and finite element methods further refine the formulation by analyzing powder flow properties, tablet compression, and dissolution behavior, with AI-driven advances improving their accuracy.

[0070] The increasing complexity of pharmaceutical production requires AI-driven optimization to improve efficiency and quality. Computational fluid dynamics assesses stirring and stress effects in equipment such as stirred tanks and optimizes production at various stages. Large-scale computer simulations address challenges related to fluid dynamics in pharmaceutical systems. An automated system known as a "Chemputer" integrates chemical synthesis with an advanced scripting platform to enable streamlined production and successfully synthesize complex compounds such as diphenhydramine and sildenafil. AI-powered granulation prediction platforms establish links between process parameters and desired outcomes, thus improving consistency across different equipment sizes.Discrete element modeling is often used to predict powder distribution, tablet encapsulation routes, and spray coating times. AI-driven metaclassifiers monitor quality deviations in real time, identify necessary adjustments, and improve production reliability. AI-powered pharmaceutical systems are also designed to personalize drug dosages and delivery mechanisms based on patient-specific data, ensuring improved therapeutic outcomes.

[0071] Maintaining consistent batch quality requires advanced monitoring of multiple variables, and AI-driven platforms offer a reliable solution. AI analyzes manufacturing data to create predictive models that improve production efficiency and quality. Artificial neural networks have been successfully implemented to predict dissolution properties in pharmaceutical formulations with high accuracy, ensuring compliance with industry standards. AI-driven inline monitoring guarantees that quality thresholds are met during production, with adaptive algorithms analyzing key factors such as temperature and product thickness in freeze-drying applications.Automated platforms, including electronic laboratory notebooks, improve the accuracy of data entry, while knowledge discovery and data mining enhance the effectiveness of pharmaceutical quality management systems.

[0072] Clinical trials play a crucial role in determining the safety and efficacy of new drugs, but they are often time-consuming and costly, with high dropout rates. AI addresses these challenges by improving patient selection and predicting drug efficacy before trials begin. AI platforms analyze genomic and exposome data to identify patients most likely to benefit from a particular treatment, thereby increasing trial success rates. Predictive machine learning models identify promising drug candidates at earlier stages, thus reducing the likelihood of failure. Patient dropout rates are a major problem in clinical trials, leading to delays and wasted resources.AI-powered mobile applications improve patient adherence, significantly increase retention rates, and contribute to study success.

[0073] AI is revolutionizing drug delivery systems through the integration of nanorobots that target specific treatment areas in the body based on physiological markers such as pH. These AI-driven nanorobots improve drug efficacy and minimize side effects. AI algorithms, including neural networks and fuzzy logic, optimize drug release and dosage, ensuring controlled and sustained delivery. In combination therapies, AI accelerates the discovery of synergistic drug pairs. AI-driven models have successfully optimized drug combinations for the treatment of drug-resistant diseases, demonstrating the technology's ability to improve treatment strategies. AI-based predictive platforms analyze drug interactions, simplifying the identification of effective combination therapies.

[0074] Despite the transformative potential of AI in pharmaceutical research and development, several challenges must be overcome. The integration of disparate and often incompatible data sets complicates AI-driven analytics and limits their full impact. The shortage of skilled professionals capable of implementing AI-based innovations presents an additional hurdle. Furthermore, the "black box" nature of AI algorithms, where decision-making processes remain opaque, raises skepticism among industry experts. AI systems require large-scale, high-quality data sets, which are costly and time-consuming to compile. Despite these obstacles, however, the adoption of AI in the pharmaceutical industry continues to grow, with growing investments driving innovation.AI-driven pharmaceutical solutions are expected to achieve significant growth, increasing industry confidence in AI's ability to transform drug development and healthcare delivery.

[0075] The drawings and the foregoing description provide examples of embodiments. Those skilled in the art will recognize that one or more of the described elements may well be combined into a single functional element. Alternatively, certain elements may be separated into multiple functional elements. Elements from one embodiment may be added to another embodiment. For example, orders of the processes described herein may be changed and are not limited to the manner described herein. Furthermore, the actions of any flowchart need not be implemented in the order shown; nor do all actions necessarily need to be performed. Also, those actions that are not dependent on other actions may be performed in parallel with the other actions. The scope of the embodiments is in no way limited by these specific examples.Numerous variations, whether explicitly stated in the specification or not, such as differences in structure, dimensions, and use of materials, are possible. The scope of the embodiments is at least as broad as indicated in the following claims.

[0076] Advantages, other benefits, and solutions to problems have been described above with reference to specific embodiments. However, the advantages, benefits, solutions to problems, and any components that may cause an advantage or solution to occur or become more apparent are not to be construed as a critical, required, or essential feature or component of any or all of the claims. REFERENCES 100 A drug discovery and development system based on artificial intelligence. 102 Data Integration Module 104 Machine Learning 106 Drug Design Module 108 Clinical Trial Optimization Module 110 Validation module 112 Production optimization module 114 Drug Administration Optimization Module 202 Artificial Intelligence 204 Healthcare 206 Lifestyle 208 Research 210 Drug administration 212 Hospital Management 214 Patient data and benefit-risk assessment 216 Mental Health 218 Operations 220 Electronic health monitoring diagnostics 222 Portable Devices 224 Machine Learning 226 Supervised Learning 228 Unsupervised Learning 230 Reinforcement Learning 232 Deep Learning

Claims

[1] An artificial intelligence system for drug discovery and development, comprising: a data integration module configured to collect and process pharmaceutical data from multiple sources, including molecular structures, protein-protein interactions, drug-protein interactions, and clinical trial data, and to standardize the collected data into a unified format; a machine learning engine configured to: analyze the standardized data using deep learning algorithms, generate predictive models for drug-protein interactions, and identify potential drug candidates based on molecular features; a drug development module configured to generate novel molecular structures using generative adversarial networks, assess the synthetic feasibility of generated molecules, and predict the biological activities of developed molecules; a clinical trial optimization module configured to: analyze patient data to select optimal study participants; predict drug efficacy based on molecular and patient-related characteristics; and create study protocols based on the predicted outcomes; and a validation module configured to evaluate the accuracy of the generated predictions, validate synthetic pathways for drug candidates, and assess the safety profiles of the developed molecules. [2] The system of claim 1, wherein the machine learning engine comprises: a deep neural network configured to analyze protein structures; a convolutional neural network configured to process molecular images; a recurrent neural network configured to generate molecular structures; and a reinforcement learning module configured to optimize molecular properties. [3] The system of claim 1, wherein the drug design module is further configured to perform retrosynthesis planning using Monte Carlo tree search algorithms, predict reaction yields for proposed synthesis routes, and optimize reaction conditions based on the predicted results. [4] The system of claim 1, wherein the data integration module is further configured to implement natural language processing to extract information from the scientific literature; maintain a knowledge graph of drug-target interactions; and update the database in real time with new experimental data. [5] The system of claim 1, wherein the clinical trial optimization module is further configured to analyze patient dropout patterns using predictive analytics, generate personalized dosing recommendations, and monitor patient compliance via mobile applications. [6] The system of claim 1, wherein the validation module is further configured to perform cross-validation using a time-split method, generate confidence values ​​for predictions, and determine potential side effects of medications through network analysis. [7] The system of claim 1, wherein the system further comprises a manufacturing optimization module configured to simulate production processes using computational fluid dynamics, optimize granulation parameters, and predict quality control results. [8] The system of claim 1, wherein the drug design module implements the following functions: quantitative structure-activity relationship (QSAR) analysis; molecular docking simulations; and binding affinity predictions using deep learning. [9] The system of claim 1, wherein the system further comprises a drug delivery optimization module configured for: designing nanobot-based delivery systems; predicting drug-drug interactions; and optimizing drug release profiles. [10] The system of claim 1, wherein the machine learning engine uses transfer learning techniques configured to use pre-trained models for sparse data scenarios, adapt learned features to different drug discovery tasks, and optimize model parameters for specific molecular targets.

Images